The 90-Year-Old "New" Fatty Acid

A fatty acid with a subscription model

Somewhere in your social feed this year, a very calm person told you that you are deficient in a nutrient you have never heard of, that this deficiency is quietly aging your cells, and that the fix is a small pink pill you can have delivered monthly for about fifty dollars.

The nutrient is pentadecanoic acid, written C15:0, an odd-chain saturated fat found mostly in whole milk, butter, and cheese. The pill is Fatty15, sold by a San Diego company called Seraphina Therapeutics. The pitch is unusually specific for a supplement: not "supports wellness," but that C15:0 is the first essential fatty acid to be discovered in over 90 years, that roughly one in three people are deficient, and that this deficiency drives a condition the company named "cellular fragility syndrome."³

That is a remarkable set of claims to build on a molecule you can get from a glass of milk. It is also, as marketing, close to perfect. It invents a disease, offers a $199 blood test to diagnose it, and then sells you the cure on autopay. So the question worth asking is not whether C15:0 exists or is interesting. It clearly is both. The question is whether any of the human evidence supports paying for it, and whether "essential" is a scientific finding or a branding decision.

It really did start with dolphins

The strangest part of the story is the part that is true. C15:0 as a supplement traces back to the U.S. Navy Marine Mammal Program, where a veterinary epidemiologist named Stephanie Venn-Watson was studying why some Navy dolphins aged into metabolic problems that looked a lot like human aging, high cholesterol, high blood sugar, fatty liver, and inflammation, while others stayed healthy.¹⁴

Her group reported that the healthier dolphins tended to eat fish higher in C15:0, and that circulating C15:0 tracked with better metabolic markers. That observation spun out into a startup, Epitracker, and then into Seraphina Therapeutics, co-founded by Venn-Watson and her husband, a Navy physician named Eric Venn-Watson.¹⁴ They licensed the work and began selling a purified free-acid form they call FA15.

None of that is disqualifying. Plenty of good drugs started as an odd animal observation. But it is worth holding onto one fact as we go: the people who first proposed that C15:0 is essential are the same people who built the company that sells it. That does not make them wrong. It does mean their papers are not disinterested, and most of the mechanistic literature carries their names.

What C15:0 plausibly does in a cell

Biochemically, odd-chain fatty acids are genuinely different from the even-chain fats that dominate your diet. When your body breaks C15:0 down, the last fragment is propionyl-CoA rather than the acetyl-CoA you get from even-chain fats. Propionyl-CoA can be converted to succinyl-CoA, which feeds directly into the citric acid cycle, the engine that mitochondria use to make energy. In principle, that gives C15:0 a small anaplerotic role, topping up the energy cycle rather than just being burned in it.⁴

On top of that plausible chemistry, the company's own cell studies report a wide list of activities. In laboratory assays, C15:0 has been described as a dual agonist of PPAR-alpha and PPAR-delta, two receptors that regulate fat metabolism and inflammation. It has been reported to activate AMPK, dial down mTOR signaling, lower mitochondrial free radicals at a specific concentration, and stabilize cell membranes against a form of iron-driven cell death called ferroptosis.^1,2,4

Taken together, that is a tidy story: an energy-supporting, membrane-stabilizing, inflammation-calming fat. And every one of those findings comes from cells in a dish or from biochemical models, most of them run by the manufacturer. A molecule that looks anti-inflammatory in twelve cell-based "disease panels" has cleared a very low bar. Aspirin, fish oil, and half your spice rack look impressive under the same conditions. The distance between "modulates PPAR in a well plate" and "extends your healthspan" is the entire field of clinical medicine.

The epidemiology is the real asset

Here is the part of the case that deserves respect. For years, nutrition epidemiologists have used blood C15:0 as an objective marker of dairy-fat intake, because your body does not make much of it and food is the main source. When they line that marker up against health outcomes in large prospective cohorts, higher C15:0 keeps showing up on the good side of the ledger.

The pattern is consistent enough that it is not nothing. But consistency is exactly what you would expect from a marker of a food that also correlates with income, cooking at home, and dozens of other things that predict health. That is the perennial problem with nutrition biomarkers, and it is why the field spent a decade wrong about saturated fat in general.

Then someone ran the actual trials

The way you break the correlation deadlock is to give people the purified molecule and see what happens. Two randomized controlled trials have now done exactly that. Neither is a takedown, but neither delivers the story the marketing promises.

Notice what both trials share. They are small. They are short. They both used more C15:0 than the 100 mg capsule sold to consumers. And neither one has ever tested C15:0 against an aging or longevity endpoint, which is the entire premise of the marketing. The supplement is sold as a healthspan intervention on the strength of zero healthspan trials.

Words that mean specific things

In nutrition science, "essential" is not a compliment. It is a technical designation for a nutrient your body cannot make in sufficient amounts, such that going without it produces a defined deficiency disease. The U.S. National Academies recognize exactly two essential fatty acids: linoleic acid, an omega-6, and alpha-linolenic acid, an omega-3. That list has been stable for decades because clearing the bar is hard.^4,11

C15:0 is not on it. No nutrition authority classifies it as essential. Outside of the company's own publications, the idea has been floated by, at most, one independent group as a "potential candidate," which is a long way from established fact. And the deficiency disease that supposedly justifies the label, "cellular fragility syndrome," along with the "one in three people are deficient" figure, appears almost entirely in Seraphina-affiliated writing.^3,11 These are coined terms, not consensus medicine.

The Center for Science in the Public Interest, which sells nothing, reviewed the whole package in 2025 and reached a blunt conclusion: the essentiality claim is unrecognized, the syndrome is invented, and the business model is to create a problem, sell a test for it, and then sell the fix. Their advice was to save your money.¹¹

Reading the fine print on the authorship

When most of a supplement's supporting science is written by the supplement's owners, you do not have to allege bad faith to be cautious. You just have to read the author lines. The foundational 2020 paper proposing essentiality, the 2022 paper claiming C15:0 outperforms omega-3 across twelve cell systems, the "cellular fragility syndrome" concept paper, and the mechanistic reviews all trace to the same small group of company-affiliated researchers.^1,2,3,4

To be fair to the molecule, the safety record is clean, the biochemistry is real, and the dairy-fat epidemiology is a legitimate scientific puzzle worth pursuing. If Seraphina ran a large, independent, longevity-endpoint trial at the marketed dose and it succeeded, I would revise this rating without hesitation. That trial does not exist yet.

Dr. Cole's assessment